Core Points - Kalaris Therapeutics, Inc. has entered into a securities purchase agreement for a private placement, aiming to raise approximately $50.0 million before expenses [1][3] - The private placement includes participation from both new and existing institutional investors [2] - Kalaris plans to use the net proceeds to fund the clinical development of TH103 for neovascular AMD and for general corporate purposes [4] Financial Details - The private placement involves the sale of 4,200,000 shares of common stock at $10.00 per share and pre-funded warrants for 800,000 shares at $9.9999 each [3] - The pricing of the securities reflects a premium over the closing price of Kalaris' common stock over the previous five trading days [3] - The transaction is expected to close on or about December 19, 2025, pending customary closing conditions [3] Company Background - Kalaris Therapeutics is focused on developing treatments for prevalent retinal diseases and was founded by Dr. Napoleone Ferrara, known for his work in anti-VEGF therapy [8]

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has filed a registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") in accordance with the ...

DUBLIN, Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events: Zanidatamab HERIZON-GEA-01 Investor Webcast on Friday, January 9, 2026 About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious disease ...

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/skye-bioscience-inc-loss-submission-form/?id=180541&from=3 CLASS PERIOD: Nov ...

BRANFORD, Conn., Dec. 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") approving Azitra's plan (the "Plan") to come into compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide. As previously reported, on October 1, 2025, Azitra rec ...

—Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program— —Company Acquires Phase 2 Ready Monoclonal Antibody for Potential Respiratory and Immunological & Inflammatory Indications— BRIDGEWATER, N.J., Dec. 17, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives ...

TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety data expected 2H 2026 K ...

Daix (France), New York City (New York, United States), December 17, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to present a corporate overview, and will engage with Inventiva’s leadership team in investor meetings, at the upcoming 44th Annual J. ...

PresentationWith that, I will hand the call over to Julian Pei, Head of Investor Relations, who will make introductory comments.Hello, ladies and gentlemen. Thank you for standing by, and welcome to our investor webcast today. As a reminder, today's call is being recorded.Julian Pei Good morning, and thank you for joining our webcast to discuss interim Phase I data from our AEROW trial in cystic fibrosis. Before we begin, I encourage everyone to visit our Investor Relations website, where you can find a pre ...

Vistagen Inc. (NASDAQ:VTGN) stock is plunging on Wednesday, with a session volume of 20.91 million compared to the average volume of 711,000, as per data from Benzinga Pro.The clinical-stage biopharmaceutical company focused on neuroscience announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not achieve its primary endpoint.PALISADE-3 public speaking challenge study was designed to evaluate the efficacy and safety of a single dose of fa ...